AMA/ASHP Pharmacogenomics Virtual Summit Series: Summit #3: Integration into Practice
Please note: This activity was given as a live webinar on February 24, 2021. If you claimed credit for that activity, you should not claim credit for this activity.
ACPE Activity Number: 0204-9999-21-006-H04-P
Release Date: 03/01/2021
Expiration Date: 02/24/2024
Activity Date: February 24, 2021
Activity Type: Knowledge-based
CE Credits: 2
Activity Fee: Free of charge
Hear from a diverse array of experts who have successfully integrated pharmacogenomics into practice – from integrating CPIC guidelines into care practices to communicating pharmacogenomic results.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was planned in cooperation with the American Medical Association.This continuing pharmacy and medical education activity is designed for healthcare professionals interested in pharmacogenomics. The activity is meant for audiences with all knowledge levels.
After participating in this activity, participants should be able to:
- Give examples of pharmacogenomic use cases from a range of practice settings
- Define laboratory technologies currently used for pharmacogenomics
- Discuss how to communicate pharmacogenomic results
- Identify strategies to provide clinicians with pharmacogenomic education
Schedule of Activities
- Laboratory Technologies – Victoria M. Pratt, Ph.D., FACMG
- Communicating Pharmacogenomic Results – Gwen McMillin, Ph.D., DABCC(CC,TC)
- Use Case #1 – Phillip Empey, Pharm.D., Ph.D.
- Use Case #2 – Nita A. Limdi, Pharm.D., Ph.D., MSHP, FAHA
- Use Case #3 – David Gregornik, B.A., B.S., Pharm.D
- Use Case #4 – Todd Skaar, M.S., Ph.D
- Education perspective – Andrew Monte, M.D., Ph.D.
- Moderated Panel Discussion
Mary V. Relling, Pharm.D., BCPS, FCCP, Member and Endowed Chair, Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital
- Gwendolyn McMillin, Ph.D., DABCC, Professor of Clinical Pathology, University of Utah
- Andrew Monte, M.D., Ph.D., Associate Professor of Emergency Medicine and Medical Toxicology at the University of Colorado and the Rocky Mountain Poison & Drug Safety Center
- Victoria M. Pratt, Ph.D., FACMG, Director, Pharmacogenomics and Molecular Genetics Laboratories | Department of Medical and Molecular Genetics | Indiana University School of Medicine
- Philip Empey, Pharm.D., Associate Director of the Institute for Precision Medicine at the University of Pittsburgh and UPMC
- Todd C. Skaar, Ph.D., Director of the Indiana Institute for Personalized Medicine
- Nita A. Limdi, Pharm.D, Ph.D, MSPH, FAHA, Professor Department of Neurology & Epidemiology Director, Program for Translational Pharmacogenomics Associate Director, Hugh Kaul Precision Medicine Institute
- David Gregornik, Pharm.D., B.A., B.S., Pharmacogenomics Program Director at Children's Minnesota
All planners, program chairs, presenters, reviewers and ASHP staff report no financial relationships relevant to this activity.
Methods and CE Requirements
This activity consists of one recorded webinar presentation. This is a 6 part series.
Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.